Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
© 2020 American Association for Cancer Research. Purpose: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1,000-fold lower e...
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
American Association for Cancer Research (AACR)
2021
|
| Online Access: | https://hdl.handle.net/1721.1/134635 |